Anna Radominska-Pandya
Concepts (433)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glucuronosyltransferase | 57 | 2019 | 122 | 9.910 |
Why?
| Microsomes, Liver | 27 | 2020 | 183 | 2.050 |
Why?
| Glucuronides | 18 | 2012 | 45 | 1.860 |
Why?
| Indoles | 15 | 2020 | 277 | 1.810 |
Why?
| Naphthalenes | 13 | 2021 | 122 | 1.800 |
Why?
| Receptor, Cannabinoid, CB1 | 9 | 2021 | 123 | 1.730 |
Why?
| Recombinant Proteins | 28 | 2020 | 477 | 1.360 |
Why?
| Tretinoin | 7 | 2008 | 51 | 1.320 |
Why?
| Cannabinoids | 10 | 2021 | 105 | 1.240 |
Why?
| Liver | 17 | 2020 | 1126 | 1.210 |
Why?
| Kinetics | 26 | 2020 | 634 | 1.130 |
Why?
| Isoenzymes | 16 | 2011 | 165 | 1.090 |
Why?
| Gene Expression Regulation, Enzymologic | 8 | 2007 | 178 | 1.020 |
Why?
| Adamantane | 3 | 2020 | 24 | 1.000 |
Why?
| Photoaffinity Labels | 11 | 2006 | 15 | 1.000 |
Why?
| Tamoxifen | 3 | 2016 | 61 | 0.990 |
Why?
| Indazoles | 3 | 2020 | 46 | 0.990 |
Why?
| Phenylalanine | 4 | 2011 | 134 | 0.870 |
Why?
| Estrogens | 5 | 2011 | 225 | 0.860 |
Why?
| Stilbenes | 3 | 2014 | 52 | 0.850 |
Why?
| Intestines | 10 | 2020 | 152 | 0.840 |
Why?
| Uridine Diphosphate Glucuronic Acid | 5 | 2019 | 9 | 0.790 |
Why?
| Intestinal Mucosa | 8 | 2011 | 214 | 0.780 |
Why?
| Warfarin | 4 | 2011 | 82 | 0.770 |
Why?
| Receptor, Cannabinoid, CB2 | 4 | 2021 | 57 | 0.740 |
Why?
| Humans | 91 | 2021 | 50419 | 0.710 |
Why?
| Microsomes | 10 | 2020 | 34 | 0.680 |
Why?
| Binding Sites | 15 | 2010 | 362 | 0.640 |
Why?
| Substrate Specificity | 15 | 2014 | 190 | 0.610 |
Why?
| Antineoplastic Agents | 6 | 2021 | 1165 | 0.610 |
Why?
| Breast Neoplasms | 6 | 2016 | 1198 | 0.570 |
Why?
| Molecular Sequence Data | 14 | 2011 | 760 | 0.560 |
Why?
| RNA, Messenger | 11 | 2008 | 1085 | 0.550 |
Why?
| Receptors, Retinoic Acid | 3 | 2002 | 22 | 0.550 |
Why?
| Chromatography, High Pressure Liquid | 12 | 2020 | 326 | 0.530 |
Why?
| Metabolic Detoxication, Phase II | 3 | 2011 | 11 | 0.520 |
Why?
| Animals | 35 | 2020 | 13063 | 0.500 |
Why?
| Hepatocytes | 3 | 2009 | 179 | 0.500 |
Why?
| Lithocholic Acid | 4 | 2005 | 20 | 0.490 |
Why?
| Oxidation-Reduction | 8 | 2020 | 313 | 0.480 |
Why?
| Selective Estrogen Receptor Modulators | 2 | 2016 | 24 | 0.460 |
Why?
| Aspartic Acid | 2 | 2007 | 50 | 0.460 |
Why?
| Nanomedicine | 1 | 2014 | 20 | 0.440 |
Why?
| Disease | 1 | 2014 | 25 | 0.440 |
Why?
| Drug Inverse Agonism | 1 | 2013 | 18 | 0.430 |
Why?
| Amino Acid Sequence | 12 | 2011 | 575 | 0.430 |
Why?
| Mass Spectrometry | 8 | 2014 | 285 | 0.430 |
Why?
| Receptors, Cytoplasmic and Nuclear | 5 | 2005 | 66 | 0.430 |
Why?
| Models, Molecular | 8 | 2011 | 333 | 0.420 |
Why?
| Pancreatic Neoplasms | 2 | 2015 | 204 | 0.410 |
Why?
| Linoleic Acids | 3 | 2001 | 8 | 0.410 |
Why?
| Mutagenesis, Site-Directed | 9 | 2011 | 96 | 0.410 |
Why?
| Digestive System | 2 | 2003 | 15 | 0.410 |
Why?
| Promoter Regions, Genetic | 2 | 2014 | 455 | 0.390 |
Why?
| Phytanic Acid | 2 | 2002 | 2 | 0.390 |
Why?
| Chromatography, Liquid | 7 | 2013 | 231 | 0.390 |
Why?
| Cytochrome P-450 CYP3A | 4 | 2020 | 77 | 0.390 |
Why?
| Docosahexaenoic Acids | 2 | 2002 | 29 | 0.390 |
Why?
| Hemiterpenes | 1 | 2011 | 11 | 0.380 |
Why?
| Receptors, Steroid | 4 | 2004 | 19 | 0.380 |
Why?
| Receptors, Cannabinoid | 1 | 2011 | 16 | 0.370 |
Why?
| Transcription Factors | 3 | 2005 | 561 | 0.370 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2014 | 468 | 0.370 |
Why?
| Tandem Mass Spectrometry | 7 | 2013 | 238 | 0.370 |
Why?
| Binding, Competitive | 7 | 2021 | 93 | 0.360 |
Why?
| Ligands | 6 | 2021 | 203 | 0.360 |
Why?
| Protein Binding | 7 | 2020 | 648 | 0.360 |
Why?
| Uridine Diphosphate | 2 | 2010 | 3 | 0.350 |
Why?
| Glucuronates | 5 | 2007 | 22 | 0.350 |
Why?
| Estradiol | 3 | 2007 | 221 | 0.340 |
Why?
| Arylsulfotransferase | 2 | 2000 | 21 | 0.340 |
Why?
| Cell Membrane | 3 | 2013 | 247 | 0.340 |
Why?
| Kidney | 2 | 2014 | 690 | 0.320 |
Why?
| Pharmaceutical Preparations | 1 | 2010 | 77 | 0.320 |
Why?
| Metabolic Networks and Pathways | 2 | 2020 | 92 | 0.310 |
Why?
| Catalysis | 7 | 2012 | 90 | 0.300 |
Why?
| Polymorphism, Genetic | 2 | 2020 | 177 | 0.300 |
Why?
| Hydroxylation | 7 | 2014 | 61 | 0.300 |
Why?
| Gastric Mucosa | 3 | 2003 | 47 | 0.300 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2008 | 568 | 0.300 |
Why?
| Acridines | 3 | 2012 | 4 | 0.300 |
Why?
| Retinoids | 1 | 2008 | 12 | 0.290 |
Why?
| Cytochrome P-450 Enzyme System | 6 | 2012 | 191 | 0.290 |
Why?
| Triazoles | 3 | 2012 | 113 | 0.280 |
Why?
| Breast | 1 | 2008 | 87 | 0.280 |
Why?
| Blotting, Western | 6 | 2008 | 575 | 0.280 |
Why?
| Cells, Cultured | 7 | 2008 | 1563 | 0.270 |
Why?
| Caco-2 Cells | 5 | 2008 | 26 | 0.270 |
Why?
| Base Sequence | 6 | 2008 | 622 | 0.260 |
Why?
| Cell Line, Tumor | 6 | 2021 | 1393 | 0.260 |
Why?
| Bile Acids and Salts | 4 | 2004 | 78 | 0.250 |
Why?
| Deoxycholic Acid | 2 | 2003 | 17 | 0.250 |
Why?
| Cloning, Molecular | 6 | 2007 | 190 | 0.240 |
Why?
| Gastrointestinal Tract | 4 | 2007 | 103 | 0.240 |
Why?
| Endoplasmic Reticulum | 3 | 2005 | 117 | 0.240 |
Why?
| CHO Cells | 3 | 2016 | 117 | 0.230 |
Why?
| Prostaglandins B | 1 | 2004 | 1 | 0.230 |
Why?
| Coumarins | 3 | 2011 | 6 | 0.230 |
Why?
| Dinoprostone | 1 | 2004 | 40 | 0.230 |
Why?
| Aminoacridines | 3 | 2012 | 4 | 0.230 |
Why?
| Gene Expression | 3 | 2005 | 605 | 0.220 |
Why?
| Structure-Activity Relationship | 5 | 2010 | 391 | 0.220 |
Why?
| Sulfotransferases | 2 | 2006 | 39 | 0.220 |
Why?
| Mice | 9 | 2020 | 5659 | 0.220 |
Why?
| Cell Line | 7 | 2004 | 997 | 0.220 |
Why?
| Protein Kinase C | 2 | 2002 | 71 | 0.220 |
Why?
| DNA Primers | 5 | 2008 | 205 | 0.220 |
Why?
| Fatty Acids | 1 | 2004 | 145 | 0.210 |
Why?
| Designer Drugs | 2 | 2013 | 22 | 0.210 |
Why?
| Catechols | 1 | 2003 | 8 | 0.210 |
Why?
| Female | 19 | 2020 | 27053 | 0.210 |
Why?
| Male | 20 | 2020 | 25866 | 0.210 |
Why?
| Carcinoma, Hepatocellular | 1 | 2005 | 191 | 0.200 |
Why?
| Cannabinoid Receptor Antagonists | 2 | 2020 | 16 | 0.200 |
Why?
| Amino Acids | 3 | 2006 | 372 | 0.200 |
Why?
| Nanotubes, Carbon | 2 | 2014 | 68 | 0.200 |
Why?
| DNA-Binding Proteins | 1 | 2005 | 410 | 0.190 |
Why?
| Nuclear Envelope | 1 | 2002 | 4 | 0.190 |
Why?
| Liver Neoplasms | 1 | 2005 | 321 | 0.190 |
Why?
| Benzoxazines | 1 | 2021 | 17 | 0.190 |
Why?
| Glutathione Transferase | 1 | 2002 | 172 | 0.190 |
Why?
| Linolenic Acids | 1 | 2001 | 1 | 0.180 |
Why?
| Sarcoma, Ewing | 1 | 2021 | 27 | 0.180 |
Why?
| Protein Structure, Tertiary | 4 | 2011 | 241 | 0.180 |
Why?
| Morpholines | 1 | 2021 | 64 | 0.180 |
Why?
| Sequence Homology, Amino Acid | 5 | 2011 | 141 | 0.180 |
Why?
| Xenobiotics | 3 | 2010 | 28 | 0.180 |
Why?
| Rats | 13 | 2012 | 3262 | 0.180 |
Why?
| Cricetinae | 4 | 2016 | 207 | 0.170 |
Why?
| Cytochrome P-450 CYP2D6 | 1 | 2020 | 22 | 0.170 |
Why?
| Biotransformation | 5 | 2012 | 84 | 0.170 |
Why?
| Molecular Structure | 5 | 2013 | 293 | 0.170 |
Why?
| Middle Aged | 12 | 2007 | 12579 | 0.170 |
Why?
| Glutamic Acid | 1 | 2000 | 109 | 0.170 |
Why?
| Sequence Alignment | 4 | 2007 | 115 | 0.160 |
Why?
| Aryl Hydrocarbon Hydroxylases | 5 | 2013 | 74 | 0.160 |
Why?
| Androgens | 1 | 1999 | 71 | 0.160 |
Why?
| Transfection | 4 | 2015 | 353 | 0.160 |
Why?
| Convulsants | 1 | 2018 | 7 | 0.150 |
Why?
| Periodic Acid | 1 | 1998 | 3 | 0.150 |
Why?
| Adult | 10 | 2007 | 13561 | 0.150 |
Why?
| Valine | 1 | 2018 | 58 | 0.150 |
Why?
| Histidine | 1 | 1998 | 15 | 0.150 |
Why?
| Intracellular Membranes | 1 | 1998 | 25 | 0.140 |
Why?
| Sex Factors | 1 | 2020 | 718 | 0.140 |
Why?
| Tritium | 3 | 2003 | 49 | 0.140 |
Why?
| Protein Isoforms | 2 | 2011 | 116 | 0.140 |
Why?
| Cricetulus | 2 | 2016 | 106 | 0.140 |
Why?
| Carrier Proteins | 2 | 2004 | 297 | 0.140 |
Why?
| Adolescent | 8 | 2006 | 6453 | 0.140 |
Why?
| Glucuronic Acid | 2 | 2011 | 8 | 0.140 |
Why?
| Methylcholanthrene | 3 | 2007 | 10 | 0.140 |
Why?
| Seizures | 1 | 2018 | 198 | 0.130 |
Why?
| Genistein | 2 | 2007 | 46 | 0.130 |
Why?
| Polymerase Chain Reaction | 2 | 2008 | 447 | 0.130 |
Why?
| Rifampin | 2 | 2007 | 59 | 0.130 |
Why?
| Stereoisomerism | 3 | 2011 | 104 | 0.120 |
Why?
| Anticoagulants | 2 | 2009 | 254 | 0.120 |
Why?
| Enzyme Induction | 4 | 2004 | 78 | 0.120 |
Why?
| Dopamine | 2 | 2008 | 174 | 0.120 |
Why?
| Solid Phase Extraction | 2 | 2013 | 12 | 0.120 |
Why?
| Down-Regulation | 2 | 2008 | 338 | 0.120 |
Why?
| MCF-7 Cells | 1 | 2015 | 62 | 0.120 |
Why?
| Mice, Inbred C57BL | 1 | 2020 | 1796 | 0.120 |
Why?
| Xanthones | 1 | 2014 | 3 | 0.120 |
Why?
| Metabolomics | 2 | 2013 | 135 | 0.120 |
Why?
| Toremifene | 1 | 2014 | 3 | 0.110 |
Why?
| Substance-Related Disorders | 2 | 2018 | 613 | 0.110 |
Why?
| Signal Transduction | 2 | 2002 | 1608 | 0.110 |
Why?
| Graphite | 1 | 2014 | 28 | 0.110 |
Why?
| Drug Carriers | 1 | 2014 | 69 | 0.110 |
Why?
| Pharmacogenetics | 1 | 2014 | 50 | 0.110 |
Why?
| Sequence Analysis, Protein | 2 | 2006 | 18 | 0.110 |
Why?
| Aged | 6 | 2007 | 9738 | 0.110 |
Why?
| Nanotechnology | 1 | 2014 | 36 | 0.110 |
Why?
| Organ Specificity | 3 | 2003 | 109 | 0.110 |
Why?
| Wounds, Stab | 1 | 2013 | 5 | 0.110 |
Why?
| Models, Chemical | 2 | 2006 | 64 | 0.110 |
Why?
| Neck Injuries | 1 | 2013 | 21 | 0.100 |
Why?
| Benzoflavones | 1 | 2013 | 3 | 0.100 |
Why?
| Sulfaphenazole | 1 | 2013 | 4 | 0.100 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2014 | 242 | 0.100 |
Why?
| Enzyme Activation | 4 | 2006 | 268 | 0.100 |
Why?
| Self-Injurious Behavior | 1 | 2013 | 30 | 0.100 |
Why?
| Phenols | 2 | 2007 | 82 | 0.100 |
Why?
| Genotype | 1 | 2014 | 525 | 0.100 |
Why?
| Biological Availability | 2 | 2011 | 102 | 0.100 |
Why?
| Cytosol | 2 | 2003 | 80 | 0.100 |
Why?
| Enzyme Inhibitors | 4 | 2019 | 369 | 0.100 |
Why?
| Crystallography, X-Ray | 2 | 2010 | 145 | 0.100 |
Why?
| Phosphoadenosine Phosphosulfate | 2 | 2003 | 3 | 0.100 |
Why?
| Metabolic Clearance Rate | 2 | 2010 | 69 | 0.100 |
Why?
| Anti-Infective Agents | 1 | 2013 | 99 | 0.100 |
Why?
| Prenylation | 1 | 2011 | 3 | 0.090 |
Why?
| Tissue Banks | 1 | 2011 | 9 | 0.090 |
Why?
| Spectrophotometry, Ultraviolet | 1 | 2011 | 32 | 0.090 |
Why?
| Oxygenases | 1 | 2011 | 14 | 0.090 |
Why?
| Ethylenediamines | 1 | 2011 | 6 | 0.090 |
Why?
| Genes, p53 | 1 | 2011 | 49 | 0.090 |
Why?
| Hydrogen-Ion Concentration | 5 | 2000 | 167 | 0.090 |
Why?
| Substance Abuse Detection | 1 | 2011 | 92 | 0.090 |
Why?
| Cell Proliferation | 1 | 2015 | 980 | 0.090 |
Why?
| Behavior, Animal | 1 | 2012 | 178 | 0.090 |
Why?
| Colon | 2 | 2003 | 95 | 0.090 |
Why?
| Peptide Fragments | 2 | 2002 | 208 | 0.090 |
Why?
| Cell Survival | 2 | 2012 | 587 | 0.080 |
Why?
| Genetic Therapy | 1 | 2011 | 120 | 0.080 |
Why?
| Hydrolysis | 2 | 2000 | 64 | 0.080 |
Why?
| Dose-Response Relationship, Drug | 3 | 2018 | 1369 | 0.080 |
Why?
| Mammals | 1 | 2010 | 50 | 0.080 |
Why?
| Uterine Cervical Neoplasms | 1 | 2012 | 275 | 0.080 |
Why?
| DNA, Complementary | 3 | 2005 | 134 | 0.080 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 2 | 2011 | 59 | 0.070 |
Why?
| Baculoviridae | 2 | 2005 | 5 | 0.070 |
Why?
| Benzoates | 1 | 2008 | 21 | 0.070 |
Why?
| Amino Acid Motifs | 1 | 2007 | 55 | 0.070 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 2007 | 43 | 0.070 |
Why?
| Naphthols | 2 | 2006 | 9 | 0.070 |
Why?
| Receptors, Estrogen | 1 | 2007 | 132 | 0.070 |
Why?
| Pyrazoles | 1 | 2007 | 111 | 0.070 |
Why?
| Lipid Metabolism | 2 | 2004 | 174 | 0.070 |
Why?
| Hymecromone | 1 | 2006 | 1 | 0.060 |
Why?
| Azides | 1 | 2006 | 10 | 0.060 |
Why?
| Phenol | 1 | 2006 | 6 | 0.060 |
Why?
| Salicylates | 1 | 2006 | 13 | 0.060 |
Why?
| Nitrophenols | 1 | 2006 | 17 | 0.060 |
Why?
| Cytochrome P-450 CYP2E1 | 1 | 2006 | 111 | 0.060 |
Why?
| Sulfates | 1 | 2006 | 24 | 0.060 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2006 | 62 | 0.060 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2004 | 120 | 0.060 |
Why?
| Up-Regulation | 1 | 2007 | 446 | 0.060 |
Why?
| Chenodeoxycholic Acid | 1 | 2005 | 7 | 0.060 |
Why?
| Oligonucleotide Probes | 1 | 2005 | 19 | 0.060 |
Why?
| Chromatography | 1 | 2005 | 11 | 0.060 |
Why?
| Isoflavones | 1 | 2006 | 89 | 0.060 |
Why?
| Child, Preschool | 2 | 2007 | 3953 | 0.060 |
Why?
| Cannabinoid Receptor Agonists | 2 | 2016 | 51 | 0.060 |
Why?
| Rats, Sprague-Dawley | 3 | 2012 | 1556 | 0.060 |
Why?
| Computer Simulation | 2 | 2006 | 273 | 0.060 |
Why?
| Hydroxyeicosatetraenoic Acids | 1 | 2004 | 18 | 0.060 |
Why?
| Receptors, Virus | 1 | 2004 | 24 | 0.060 |
Why?
| Heme | 2 | 2003 | 21 | 0.060 |
Why?
| GTP-Binding Proteins | 2 | 2016 | 94 | 0.060 |
Why?
| Ketoprofen | 2 | 2004 | 2 | 0.060 |
Why?
| Cell Nucleus | 2 | 2001 | 183 | 0.050 |
Why?
| Child | 3 | 2003 | 6931 | 0.050 |
Why?
| Plasmids | 1 | 2004 | 159 | 0.050 |
Why?
| Drug Interactions | 1 | 2004 | 207 | 0.050 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 831 | 0.050 |
Why?
| Dehydroepiandrosterone | 1 | 2003 | 14 | 0.050 |
Why?
| Brain | 3 | 2020 | 1318 | 0.050 |
Why?
| Steroids | 1 | 2003 | 57 | 0.050 |
Why?
| Cytochrome P-450 CYP1A2 | 2 | 2013 | 38 | 0.050 |
Why?
| Glycosylation | 1 | 2003 | 103 | 0.050 |
Why?
| Chromatography, Thin Layer | 2 | 2001 | 24 | 0.050 |
Why?
| Glutathione S-Transferase pi | 1 | 2002 | 24 | 0.050 |
Why?
| Retinoid X Receptors | 1 | 2002 | 13 | 0.050 |
Why?
| Intestine, Small | 1 | 2003 | 110 | 0.050 |
Why?
| Inhibitory Concentration 50 | 2 | 2012 | 68 | 0.050 |
Why?
| Receptors, LDL | 1 | 2002 | 67 | 0.050 |
Why?
| Fluorescent Antibody Technique | 1 | 2002 | 109 | 0.050 |
Why?
| Reference Values | 1 | 2002 | 302 | 0.050 |
Why?
| Carcinogens | 1 | 2003 | 196 | 0.050 |
Why?
| Cytotoxins | 1 | 2021 | 15 | 0.050 |
Why?
| Cholesterol | 1 | 2002 | 150 | 0.050 |
Why?
| Autoradiography | 1 | 2001 | 33 | 0.050 |
Why?
| Stomach | 1 | 2002 | 81 | 0.050 |
Why?
| Microscopy, Fluorescence | 1 | 2002 | 160 | 0.050 |
Why?
| Ascitic Fluid | 1 | 2001 | 12 | 0.040 |
Why?
| Isoxazoles | 1 | 2000 | 14 | 0.040 |
Why?
| Indicators and Reagents | 1 | 2000 | 37 | 0.040 |
Why?
| Estriol | 1 | 2000 | 3 | 0.040 |
Why?
| Cholestasis | 1 | 2001 | 40 | 0.040 |
Why?
| Blotting, Northern | 1 | 2000 | 109 | 0.040 |
Why?
| Immunophenotyping | 1 | 2001 | 106 | 0.040 |
Why?
| Glucosyltransferases | 1 | 2000 | 6 | 0.040 |
Why?
| Metalloendopeptidases | 1 | 2000 | 69 | 0.040 |
Why?
| Cattle | 1 | 2000 | 196 | 0.040 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2001 | 77 | 0.040 |
Why?
| Tryptophan | 1 | 2000 | 100 | 0.040 |
Why?
| Lysine | 1 | 2000 | 84 | 0.040 |
Why?
| Lymphocytes | 1 | 2001 | 153 | 0.040 |
Why?
| RNA | 1 | 2000 | 164 | 0.040 |
Why?
| Affinity Labels | 1 | 1999 | 5 | 0.040 |
Why?
| Glutamine | 1 | 2000 | 175 | 0.040 |
Why?
| Conserved Sequence | 1 | 1999 | 52 | 0.040 |
Why?
| Catalytic Domain | 1 | 1999 | 57 | 0.040 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 98 | 0.040 |
Why?
| Fluorescent Dyes | 1 | 1999 | 106 | 0.040 |
Why?
| Arginine | 1 | 2000 | 185 | 0.040 |
Why?
| Immunohistochemistry | 1 | 2002 | 955 | 0.040 |
Why?
| Androsterone | 1 | 1998 | 2 | 0.040 |
Why?
| Phosphorus Radioisotopes | 1 | 1998 | 8 | 0.040 |
Why?
| Tyrosine | 1 | 1999 | 92 | 0.040 |
Why?
| Jejunum | 1 | 1998 | 55 | 0.040 |
Why?
| Imidazoles | 1 | 1999 | 125 | 0.040 |
Why?
| Ileum | 1 | 1998 | 85 | 0.040 |
Why?
| Isotope Labeling | 1 | 1998 | 54 | 0.040 |
Why?
| Diethyl Pyrocarbonate | 1 | 1998 | 1 | 0.040 |
Why?
| Uridine Diphosphate Sugars | 1 | 1998 | 1 | 0.040 |
Why?
| Testosterone | 1 | 1998 | 145 | 0.040 |
Why?
| Acetophenones | 1 | 1998 | 11 | 0.040 |
Why?
| Nitro Compounds | 1 | 1998 | 8 | 0.040 |
Why?
| Benzenesulfonates | 1 | 1998 | 10 | 0.040 |
Why?
| Cross-Linking Reagents | 1 | 1998 | 41 | 0.040 |
Why?
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2016 | 15 | 0.030 |
Why?
| Isomerism | 1 | 2016 | 24 | 0.030 |
Why?
| Cyclohexanols | 1 | 2016 | 21 | 0.030 |
Why?
| Ovarian Neoplasms | 1 | 2001 | 449 | 0.030 |
Why?
| Cyclic AMP | 1 | 2016 | 90 | 0.030 |
Why?
| Models, Biological | 2 | 2012 | 717 | 0.030 |
Why?
| L-Lactate Dehydrogenase | 1 | 2014 | 61 | 0.030 |
Why?
| Microscopy, Electron, Transmission | 1 | 2014 | 73 | 0.030 |
Why?
| Pentanones | 1 | 2013 | 7 | 0.030 |
Why?
| Paper | 1 | 2013 | 15 | 0.030 |
Why?
| Capsules | 1 | 2013 | 28 | 0.030 |
Why?
| Powders | 1 | 2013 | 22 | 0.030 |
Why?
| Methylamines | 1 | 2013 | 17 | 0.030 |
Why?
| Tablets | 1 | 2013 | 31 | 0.030 |
Why?
| Bilirubin | 2 | 2004 | 41 | 0.030 |
Why?
| Tissue Distribution | 1 | 2013 | 167 | 0.030 |
Why?
| Benzodioxoles | 1 | 2013 | 41 | 0.030 |
Why?
| Pyrrolidines | 1 | 2013 | 67 | 0.030 |
Why?
| Hallucinogens | 1 | 2013 | 65 | 0.030 |
Why?
| Fatal Outcome | 1 | 2013 | 197 | 0.030 |
Why?
| Pyrans | 1 | 2012 | 16 | 0.020 |
Why?
| Drug Partial Agonism | 1 | 2012 | 6 | 0.020 |
Why?
| Drug Antagonism | 1 | 2012 | 8 | 0.020 |
Why?
| HeLa Cells | 1 | 2012 | 257 | 0.020 |
Why?
| Body Temperature | 1 | 2012 | 67 | 0.020 |
Why?
| Alcohols | 1 | 2011 | 8 | 0.020 |
Why?
| Mice, Inbred Strains | 1 | 2012 | 159 | 0.020 |
Why?
| Biocatalysis | 1 | 2011 | 13 | 0.020 |
Why?
| Macrophages | 1 | 2014 | 365 | 0.020 |
Why?
| Hep G2 Cells | 1 | 2011 | 36 | 0.020 |
Why?
| Neoplasms | 1 | 2001 | 1248 | 0.020 |
Why?
| Thermogravimetry | 1 | 2011 | 7 | 0.020 |
Why?
| Deuterium | 1 | 2011 | 45 | 0.020 |
Why?
| Reference Standards | 1 | 2011 | 52 | 0.020 |
Why?
| Methamphetamine | 1 | 2013 | 195 | 0.020 |
Why?
| Microscopy, Atomic Force | 1 | 2011 | 25 | 0.020 |
Why?
| Microscopy, Electron, Scanning | 1 | 2011 | 47 | 0.020 |
Why?
| Cell Hypoxia | 1 | 2011 | 82 | 0.020 |
Why?
| Glucuronidase | 1 | 2011 | 47 | 0.020 |
Why?
| Central Nervous System Stimulants | 1 | 2013 | 209 | 0.020 |
Why?
| Caspase 3 | 1 | 2011 | 93 | 0.020 |
Why?
| Staining and Labeling | 1 | 2011 | 97 | 0.020 |
Why?
| Green Fluorescent Proteins | 1 | 2011 | 90 | 0.020 |
Why?
| Mitochondria | 1 | 2014 | 400 | 0.020 |
Why?
| Tissue Donors | 1 | 2011 | 121 | 0.020 |
Why?
| Analysis of Variance | 1 | 2011 | 549 | 0.020 |
Why?
| Drug Delivery Systems | 1 | 2011 | 143 | 0.020 |
Why?
| Mice, Knockout | 2 | 2003 | 840 | 0.020 |
Why?
| Gene Expression Regulation | 2 | 2004 | 948 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2011 | 855 | 0.020 |
Why?
| Neurons | 1 | 2012 | 445 | 0.020 |
Why?
| DNA Mutational Analysis | 1 | 2007 | 175 | 0.020 |
Why?
| Mutation | 1 | 2012 | 1275 | 0.020 |
Why?
| Bacillus subtilis | 1 | 1975 | 5 | 0.020 |
Why?
| Glycoside Hydrolases | 1 | 1975 | 20 | 0.020 |
Why?
| Ethers | 1 | 1975 | 8 | 0.020 |
Why?
| Digitoxin | 1 | 1975 | 3 | 0.020 |
Why?
| Apoptosis | 1 | 2011 | 1092 | 0.020 |
Why?
| Pentosephosphates | 1 | 1975 | 1 | 0.020 |
Why?
| Glucosephosphate Dehydrogenase Deficiency | 1 | 1975 | 3 | 0.020 |
Why?
| Sodium Salicylate | 1 | 1975 | 4 | 0.020 |
Why?
| Formates | 1 | 1975 | 4 | 0.020 |
Why?
| Body Fluids | 1 | 1975 | 19 | 0.020 |
Why?
| Etodolac | 1 | 2004 | 1 | 0.010 |
Why?
| Naproxen | 1 | 2004 | 7 | 0.010 |
Why?
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2004 | 1 | 0.010 |
Why?
| Enzymes | 1 | 2004 | 29 | 0.010 |
Why?
| Schizophrenia | 1 | 1976 | 258 | 0.010 |
Why?
| Species Specificity | 1 | 2004 | 182 | 0.010 |
Why?
| Antipsychotic Agents | 1 | 1976 | 233 | 0.010 |
Why?
| Young Adult | 1 | 2013 | 4075 | 0.010 |
Why?
| Administration, Oral | 1 | 2004 | 438 | 0.010 |
Why?
| Exons | 1 | 2003 | 94 | 0.010 |
Why?
| Oligodeoxyribonucleotides, Antisense | 1 | 2002 | 2 | 0.010 |
Why?
| Protein Kinase C-epsilon | 1 | 2002 | 4 | 0.010 |
Why?
| Diglycerides | 1 | 2002 | 9 | 0.010 |
Why?
| Type C Phospholipases | 1 | 2002 | 13 | 0.010 |
Why?
| Eicosanoids | 1 | 2002 | 16 | 0.010 |
Why?
| Phospholipids | 1 | 2002 | 55 | 0.010 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2002 | 154 | 0.010 |
Why?
| Mice, Transgenic | 1 | 2003 | 537 | 0.010 |
Why?
| Tumor Cells, Cultured | 1 | 2002 | 453 | 0.010 |
Why?
| Oxidoreductases, N-Demethylating | 1 | 2001 | 32 | 0.010 |
Why?
| CD4-CD8 Ratio | 1 | 2001 | 9 | 0.010 |
Why?
| Lymphocyte Subsets | 1 | 2001 | 14 | 0.010 |
Why?
| Lymphocyte Count | 1 | 2001 | 19 | 0.010 |
Why?
| Interleukin-4 | 1 | 2001 | 42 | 0.010 |
Why?
| Transcription, Genetic | 1 | 2002 | 354 | 0.010 |
Why?
| Interleukin-2 | 1 | 2001 | 70 | 0.010 |
Why?
| Spodoptera | 1 | 2000 | 5 | 0.010 |
Why?
| Carbohydrate Conformation | 1 | 2000 | 4 | 0.010 |
Why?
| Acid Phosphatase | 1 | 2000 | 12 | 0.010 |
Why?
| Interferon-gamma | 1 | 2001 | 175 | 0.010 |
Why?
| Glycoproteins | 1 | 2000 | 116 | 0.010 |
Why?
| Saccharomyces cerevisiae | 1 | 2000 | 173 | 0.010 |
Why?
| Antibodies | 1 | 1999 | 151 | 0.010 |
Why?
| Flow Cytometry | 1 | 2001 | 472 | 0.010 |
Why?
| Aged, 80 and over | 1 | 2001 | 3233 | 0.010 |
Why?
| Time Factors | 2 | 1975 | 2933 | 0.000 |
Why?
| Promazine | 1 | 1976 | 1 | 0.000 |
Why?
| Chlorpromazine | 1 | 1976 | 14 | 0.000 |
Why?
| Basal Ganglia Diseases | 1 | 1976 | 6 | 0.000 |
Why?
| Nitrophenylgalactosides | 1 | 1975 | 1 | 0.000 |
Why?
| Arabinose | 1 | 1975 | 2 | 0.000 |
Why?
| Trifluoperazine | 1 | 1976 | 6 | 0.000 |
Why?
| Movement Disorders | 1 | 1976 | 14 | 0.000 |
Why?
| Mercury | 1 | 1975 | 6 | 0.000 |
Why?
| Glucosides | 1 | 1975 | 16 | 0.000 |
Why?
| Chromatography, Gel | 1 | 1975 | 39 | 0.000 |
Why?
| Ethyl Ethers | 1 | 1975 | 1 | 0.000 |
Why?
| Benzopyrenes | 1 | 1975 | 2 | 0.000 |
Why?
| NADPH-Ferrihemoprotein Reductase | 1 | 1975 | 14 | 0.000 |
Why?
| Phenobarbital | 1 | 1975 | 17 | 0.000 |
Why?
| Oligosaccharides | 1 | 1975 | 34 | 0.000 |
Why?
| Digitoxigenin | 1 | 1975 | 4 | 0.000 |
Why?
| NADP | 1 | 1975 | 22 | 0.000 |
Why?
| Aldehyde Oxidoreductases | 1 | 1975 | 2 | 0.000 |
Why?
| Methanol | 1 | 1975 | 9 | 0.000 |
Why?
| Haplorhini | 1 | 1975 | 24 | 0.000 |
Why?
| Pseudomonas | 1 | 1975 | 5 | 0.000 |
Why?
| Methods | 1 | 1975 | 56 | 0.000 |
Why?
| Methylene Blue | 1 | 1975 | 9 | 0.000 |
Why?
| Erythrocytes | 1 | 1975 | 82 | 0.000 |
Why?
| Carbon Dioxide | 1 | 1975 | 94 | 0.000 |
Why?
| Recurrence | 1 | 1976 | 657 | 0.000 |
Why?
| Chronic Disease | 1 | 1976 | 573 | 0.000 |
Why?
| Clinical Trials as Topic | 1 | 1976 | 488 | 0.000 |
Why?
| Blood Glucose | 1 | 1975 | 447 | 0.000 |
Why?
|
|
Radominska-Pandya's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|